Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Requests More Information, Needs More Time To Review Birth Control OTC Switch Proposal

Oct 27 2022

• By Malcolm Spicer

• Source: Shutterstock

Related Content

Zejula, Revatio Advisory Committee Meetings Cancelled; Palovarotene Panel Postponed

Oct 26 2022

OTC Daily Oral Contraceptive Proposal In US Packs Promise Of Access, But Peril Of Single Option

Aug 23 2022

Comments Make Clear Jewish Women’s Group Supports OTC Daily Oral Contraceptive Approval

Oct 27 2022

Will Influences Behind US FDA's Delayed Approval For OTC Plan B Also Shadow ‘Plan A’ Switch?

Jul 12 2022

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Jul 12 2022

Perrigo Continues Overhaul Adding HRA Pharma, Boosts Chances For OTC Oral Contraceptive In US

Sep 09 2021

Related Companies

Perrigo Company PLC

Additional Topics

International Ireland Europe United States France Advisory Committees FDA Prescription To OTC Switch Advertising, Marketing & Sales Business Strategies Commercial Companies Compliance Consumer Drug Approval Standards Drug Review Ingredients Manufacturing OTC Drugs Policy Politics Regulation User Fees Gynecology & Urology

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window